Three CDK4/6 inhibitors are approved for the treatment of oestrogen receptor-positive (ER+) breast cancer and our results support further preclinical examination of a CDK4/6 inhibitor in combination with lapatinib or tucatinib. Here, CDK4 is linked to breast carcinoma.